Tech and chip stocks plunged following the U.S. midterm elections as investors worried about potential AI regulation and data center development under the new Democratic majority. The Nasdaq Composite fell into correction territory but rebounded slightly the next day. Meanwhile, U.S. economic data showed stronger-than-expected job growth in October, with 165,000 jobs added and unemployment dropping to 4.1%, signaling a resilient labor market despite wage growth lagging behind inflation. Investors are balancing political risks with positive economic signals as the market adjusts to the new landscape.
Nasdaq and chip stocks provide context for Pluang's tech sector data. For readers following technology stocks, here is Pluang's market snapshot as of Nov 06, 2026 21:31 WIB: Out of 150 priced tech stocks, 81 rose and 68 fell. Notable movers include WK at USD 70.48 with a -17.49% change, TEAM at USD 156.50 down -14.62% with 88% buy orders, and CIFR at USD 6.25 up 12.61% with 54% sell orders.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
